Stable Isotope-Resolved Metabolomics in Elucidating Mitochondrial Metabolic Reprogramming and Therapeutic Targets.
Stable Isotope-Resolved Metabolomics in Elucidating Mitochondrial Metabolic Reprogramming and Therapeutic Targets.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Yibin, CN · Author affiliation
Engineering Center of Agricultural Biosafety Assessment and Biotechnology, School of Advanced Agricultural Sciences, Yibin Vocational and Technical College, Yibin, China.Location evidence
Beijing, CN · Author affiliation
College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.Location evidence
Dazhou, CN · Author affiliation
Geriatric Department, Dazhou Central Hospital, Dazhou, China.Location evidence
Hangzhou, CN · Author affiliation
Institute of Hematology, Zhejiang University, Hangzhou, China.Location evidence
Shenyang, CN · Author affiliation
College of Life and Health Science, Northeastern University, Shenyang, China.Location evidence
Shenzhen, CN · Author affiliation
Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.Location evidence
Baotou, CN · Author affiliation
Inner Mongolia Key Laboratory of Life Health and Bioinformatics, School of Life Science and Technology, Inner Mongolia University of Science and Technology, Baotou, China.Location evidence
MN · Author affiliation · country only
Inner Mongolia Key Laboratory of Life Health and Bioinformatics, School of Life Science and Technology, Inner Mongolia University of Science and Technology, Baotou, China.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Stable isotope-resolved metabolomics (SIRM) has emerged as a pivotal methodology for dissecting mitochondrial metabolic reprogramming and its connection to therapeutic targets. By combining isotopically labeled substrates with metabolic flux analysis (MFA), SIRM enables dynamic, quantitative tracking of carbon flux through mitochondrial pathways. This review focuses on three disease contexts where SIRM has provided transformative insights: cancer, neurodegenerative disorders (Alzheimer's and Parkinson's diseases), and metabolic syndrome (type 2 diabetes and non-alcoholic fatty liver disease). Recent applications have delineated reprogramming signatures, identified metabolic dependencies, and elucidated drug mechanisms. SIRM also facilitates therapeutic monitoring and resistance assessment, offering quantitative biomarkers for patient stratification. We summarize recent advances, technical challenges, AI-powered innovations, and future directions, providing a foundation for optimizing metabolism-targeted therapies.